WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 206423
CAS#: 1228013-30-6
Description: Onatasertib, also known as CC-223, is an orally available inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor CC-223 inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/AKT/mTOR signaling pathway, which is frequently dysregulated in human cancers.
MedKoo Cat#: 206423
Name: CC-223
CAS#: 1228013-30-6
Chemical Formula: C21H27N5O3
Exact Mass: 397.21139
Molecular Weight: 397.48
Elemental Analysis: C, 63.46; H, 6.85; N, 17.62; O, 12.08
Related CAS #: 1228013-30-6
Synonym: CC-223; CC 223; CC223; Onatasertib;
IUPAC/Chemical Name: 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((1r,4r)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one
InChi Key: UFKLYTOEMRFKAD-SHTZXODSSA-N
InChi Code: InChI=1S/C21H27N5O3/c1-21(2,28)17-9-4-13(10-22-17)16-11-23-19-20(25-16)26(18(27)12-24-19)14-5-7-15(29-3)8-6-14/h4,9-11,14-15,28H,5-8,12H2,1-3H3,(H,23,24)/t14-,15-
SMILES Code: OC(C)(C)C(N=C1)=CC=C1C(N=C2N3[C@@H]4CC[C@H](CC4)OC)=CN=C2NCC3=O
Appearance: Red to pink solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 397.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T,
Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS,
Chopra R, Hege K, Munster PN. A phase I dose-escalation study to assess safety,
tolerability, pharmacokinetics, and preliminary efficacy of the dual
mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or
multiple myeloma. Cancer. 2015 Oct 1;121(19):3481-90. doi: 10.1002/cncr.29422.
Epub 2015 Jul 15. PubMed PMID: 26177599.
2: Mortensen DS, Perrin-Ninkovic SM, Shevlin G, Zhao J, Packard G, Bahmanyar S,
Correa M, Elsner J, Harris R, Lee BG, Papa P, Parnes JS, Riggs JR, Sapienza J,
Tehrani L, Whitefield B, Apuy J, Bisonette RR, Gamez JC, Hickman M, Khambatta G,
Leisten J, Peng SX, Richardson SJ, Cathers BE, Canan SS, Moghaddam MF, Raymon HK,
Worland P, Narla RK, Fultz KE, Sankar S. Discovery of mammalian target of
rapamycin (mTOR) kinase inhibitor CC-223. J Med Chem. 2015 Jul 9;58(13):5323-33.
doi: 10.1021/acs.jmedchem.5b00626. Epub 2015 Jun 26. PubMed PMID: 26083478.
3: Mortensen DS, Fultz KE, Xu S, Xu W, Packard G, Khambatta G, Gamez JC, Leisten
J, Zhao J, Apuy J, Ghoreishi K, Hickman M, Narla RK, Bissonette R, Richardson S,
Peng SX, Perrin-Ninkovic S, Tran T, Shi T, Yang WQ, Tong Z, Cathers BE, Moghaddam
MF, Canan SS, Worland P, Sankar S, Raymon HK. CC-223, a Potent and Selective
Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization. Mol Cancer Ther.
2015 Jun;14(6):1295-305. doi: 10.1158/1535-7163.MCT-14-1052. Epub 2015 Apr 8.
PubMed PMID: 25855786.
4: Ashworth RE, Wu J. Mammalian target of rapamycin inhibition in hepatocellular
carcinoma. World J Hepatol. 2014 Nov 27;6(11):776-82. doi:
10.4254/wjh.v6.i11.776. Review. PubMed PMID: 25429315; PubMed Central PMCID:
PMC4243151.
(last updated: 4/19/2016)
